News
Updated and committed to information
VALIDATION OF A 22-GENE GENOMIC CLASSIFIER IN PATIENTS WITH RECURRENT PROSTATE CANCER
In this ancillary analysis of the RTOG 9601 study, the researchers validated a 22-gene genomic classifier panel as a predictive biomarker for distant metastases in
6Q DELETION IN WALDENSTRÖM MACROGLOBULINAEMIA NEGATIVELY AFFECTS TIME TO TRANSFORMATION AND SURVIVAL
Deletion of the long arm of chromosome 6 (del6q) is the most frequent cytogenetic abnormality in Waldenström macroglobulinaemia (WM), occurring in approximately 50% of patients.
FDA APPROVES FAM-TRASTUZUMAB DERUXTECAN-NXKI FOR HER2-POSITIVE GASTRIC ADENOCARCINOMAS
On January 15, 2021, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for adult patients with locally advanced or metastatic HER2-positive gastric
FIRST-LINE LORLATINIB OR CRIZOTINIB IN ADVANCED ALK-POSITIVE LUNG CANCER
In a study published online in The New England Journal of Medicine, Alice T. Shaw and coauthors presented the results of CROWN, a phase III trial
MUTANT IDH1 INHIBITOR IVOSIDENIB COMBINED WITH AZACITIDINE FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
The authors of this phase Ib trial evaluated the oral IDH1 inhibitor ivosidenib in combination with azacitidine in 23 patients with newly diagnosed acute myeloid
OLAPARIB FOR METASTATIC BREAST CANCER AND MUTATIONS IN HOMOLOGOUS RECOMBINATION–RELATED GENES
The authors of this phase II trial evaluated the PARP inhibitor olaparib in the treatment of 54 patients with metastatic breast cancer (76% ER-positive/HER2-negative) and
